Abstract
Aim:
Cathepsin L (CTSL), a lysosomal acid cysteine protease, is known to play important roles in tumor metastasis and chemotherapy resistance. In this study we investigated the molecular mechanisms underlying the regulation of chemoresistance by CTSL in human lung cancer cells.
Methods:
Human lung cancer A549 cells, A549/PTX (paclitaxel-resistant) cells and A549/DDP (cisplatin-resistant) cells were tested. The resistance to cisplatin or paclitaxel was detected using MTT and the colony-formation assays. Actin remodeling was observed with FITC-Phalloidin fluorescent staining or immunofluorescence. A wound-healing assay or Transwell assay was used to assess the migration or invasion ability. The expression of CTSL and epithelial and mesenchymal markers was analyzed with Western blotting and immunofluorescence. The expression of EMT-associated transcription factors was measured with Western blotting or q-PCR. BALB/c nude mice were implanted subcutaneously with A549 cells overexpressing CTSL, and the mice were administered paclitaxel (10, 15 mg/kg, ip) every 3 d for 5 times.
Results:
Cisplatin or paclitaxel treatment (10–80 ng/mL) induced CTSL expression in A549 cells. CTSL levels were much higher in A549/PTX and A549/DDP cells than in A549 cells. Silencing of CTSL reversed the chemoresistance in A549/DDP and A549/TAX cells, whereas overexpression of CTSL attenuated the sensitivity of A549 cells to cisplatin or paclitaxel. Furthermore, A549/DDP and A549/TAX cells underwent morphological and cytoskeletal changes with increased cell invasion and migration abilities, accompanied by decreased expression of epithelial markers (E-cadherin and cytokeratin-18) and increased expression of mesenchymal markers (N-cadherin and vimentin), as well as upregulation of EMT-associated transcription factors Snail, Slug, ZEB1 and ZEB2. Silencing of CTSL reversed EMT in A549/DDP and A549/TAX cells; In contrast, overexpression of CTSL induced EMT in A549 cells. In xenograft nude mouse model, the mice implanted with A549 cells overexpressing CTSL exhibited significantly reduced sensitivity to paclitaxel treatment, and increased expression of EMT-associated proteins and transcription factors in tumor tissues.
Conclusion:
Cisplatin and paclitaxel resistance is associated with CTSL upregulation-induced EMT in A549 cells. Thus, CTSL-mediated EMT may be exploited as a target to enhance the efficacy of cisplatin or paclitaxel against lung cancer and other types of malignancies.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kallianos A, Tsimpoukis S, Zarogoulidis P, Darwiche K, Charpdou A, Tsioulis I, et al. Measurement of exhaled alveolar nitrogen oxide in patients with lung cancer: a friend from the past still precious today. Onco Targets Ther 2013; 6: 609–13.
Maslyar DJ, Jahan TM, Jablons DM . Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2004; 16: 40–50.
Smith W, Khuri FR . The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 2004; 31: 11–5.
Liu J, Meisner D, Kwong E, Wu XY, Johnston MR . Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res 2009; 69: 1174–81.
Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH . Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012; 7: 1361–8.
Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1786–93.
Yin S, Zeng C, Hari M, Cabral F . Paclitaxel resistance by random mutagenesis of alpha-tubulin. Cytoskeleton 2013; 70: 849–62.
Zuo KQ, Zhang XP, Zou J, Li D, Lv ZW . Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res 2010; 38: 1428–35.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869–83.
Lee HY, Mohammed KA, Goldberg EP, Kaye F, Nasreen N . Cisplatin loaded albumin mesospheres for lung cancer treatment. Am J Cancer Res 2015; 5: 603–15.
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257.
Brozovic A, Osmak M . Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251: 1–16.
Shang Y, Cai X, Fan D . Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets 2013; 13: 915–29.
Singh A, Settleman J . EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–51.
Zaravinos A . The regulatory role of microRNAs in EMT and cancer. J Oncol 2015; 2015: 865816.
Ylimaz M, Christofori G . EMT, the cytoskeleton, and cancer cell invasion. Cancer Matastasis Rev 2009; 28: 15–23.
Thiery JP . Epithelial-mesenchymal transtion in tumor progression. Nat Rev Cancer 2002; 2: 442–54.
Hiroaki K, Kiyosumi S . Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277–83.
Nurwidya F, Takahashi F, Murakami A, Takahashi K . Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012; 44: 151–6.
Zhang Q, Han M, Wang W, Song Y, Chen G, Wang Z, et al. Downregulation of cathepsin L suppresses cancer invasion and migration by inhibiting transforming growth factor-β-mediated epithelial-mesenchymal transition. Oncol Rep 2015; 33: 1851–9.
Taqi C, Gover S, Dhanjal J, Goyal S, Goyal M, Grover A . Mechanistic insights into mode of action of novel natural cathepsin L inhibitors. BMC Gennomics 2013; 14: S10.
Tholen M, Wlianski J, Stolze B, Chiabudini M, Gajda M, Bronsert P, et al. Stress-resistant translation of cathepsin L mRNA in breast cancer progression. J Biol Chem 2015; 290: 15758–69.
Brix K, Dunkhorst A, Mayer K, Jordan S . Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008; 90: 194–207.
Bylaite M, Moussali H, Marciukaitiene I, Ruzicka T, Walz M . Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Exp Dermatol 2006; 15: 110–8.
Stahl S, Reinders Y, Asan E, Mothes W, Conzelmann E, Sickmann A, et al. Proteomic analysis of cathepsin B-and L-deficient mouse brain lysosomes. Biochimica Biophysica Acta 2007; 1774: 1237–46.
Zheng X, Chou PM, Mirkin BL, Rebbaa A . Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Biochim Biophys Acta Cancer Res 2004; 64: 1773.
Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, et al. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 2009; 296: C65–74.
Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J Cell Biochem 2013; 114: 1286–93.
Liu S, Ye D, Xu D, Liao Y, Zhang L, Liu L, et al. Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma. Oncotarget 2016; 7: 25251–63.
Beerling E, Seinstra D, de Wit E, Kester L, van der Velden D, Maynard C, et al. Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep 2016; 14: 2281–8.
Gonçalves Ndo N, Colombo J, Lopes JR, Gelaleti GB, Moschetta MG, Sonehara NM, et al. Effect of melatonin in epithelial mesenchymal transition markers and invasive properties of breast cancer stem cells of canine and human cell lines. PLoS One 2016; 11: e0150407.
Lin SY, Lee YX, Yu SL, Chang GC, Chen JJ . Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition. Oncotarget 2016; 7: 21799–811.
Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, et al. High throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non small cell lung cancer. J Clin Oncol 2002; 20: 2417–28.
Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol 2012; 25: 86–99.
Vouligari A, Pintzas A . Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009; 1796: 75–90.
Smith A, Teknos TN, Pan Q . Epithelial to mesenchymal transition in head and neck spuamous cell carcinoma. Oral Oncol 2013; 49: 287–92.
Liao H, Bai Y, Qiu S, Zheng L, Huang L, Liu T, et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via snail2. Oncotarget 2015; 6: 8914–28.
Byles V, Zhu L, Lovaas JD, Chmilewski LK, Wang J, Faller DV, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene 2012; 31: 4619–29.
Pettitt J . The cadherin superfamily. WormBook 2005; 1–9.
Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, et al. Delta EF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375–85.
Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569–81.
Thiery JP . Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002; 2: 442–54.
Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–51.
Peinado H, Olmeda D, Cano A . Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415–28.
Jia J, Zhang W, Liu JY, Chen G, Liu H, Zhong HY, et al. Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS One 2012; 7: e51549.
Thiery JP, Sleeman JP . Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131–42.
Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569–81.
Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–96.
Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B . Rab7: A key to lysosome biogenesis. Mol Biol Cell 2000; 11: 467–80.
Huang DS, Duan HY . Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial mesenchymal transition. Sci Rep 2016; 6: 20502.
Yang J, Weinberg RA . Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818–29.
Savanger P . Leaving the neighborhood: molecular mechanisms involved during eipthelial-mesenchymal transition. Bioessays 2001; 23: 912–23.
Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, et al. Distinct roles for systeine cathepsin genes in multistage tumorigenesis. Genes Dev 2006; 20: 543–56.
Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931–40.
Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM . Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 2008; 318: 89–99.
De Herreros AG, Peiro S, Nassour M, Savagner P . Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 2010; 15: 135–47.
Kedinger V, Nepveu A . The roles of CUX1 homeodomain proteins in the establishment of a transcriptional program required for cell migration and invasion. Cell Adh Migr 2010; 4: 348–52.
Kedinger V, Sansreqret L, Harada R, Vadnais C, Cadieux C, Fathers K, et al. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. J Biol Chem 2009; 284: 27701–11.
Ramdzan ZM, Nepveu A . CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers. Nat Rev Cancer 2014; 14: 673–82.
Barbera MJ, Puig I, Dominguez D, Julien-Grille S, Guaita-Esteruelas S, Peiro S, et al. Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells. Oncogene 2004; 23: 7345–54.
Yang N, Wang P, Wang WJ, Song YZ, Liang ZQ . Inhibition of cathepsin L sensitizes human glioma cells to ionizing radiation in vitro through NF-κB signaling pathway. Acta Pharmacol Sin 2015; 36: 400–10.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (Grant No 30873052, 81072656, 81102466, and 81373430) and the Outstanding Medical Academic Leader Program of Jiangsu Province (Grant No LJ201139).
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
About this article
Cite this article
Han, Ml., Zhao, Yf., Tan, Ch. et al. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin 37, 1606–1622 (2016). https://doi.org/10.1038/aps.2016.93
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.93
Keywords
This article is cited by
-
Role of microRNAs in regulation of doxorubicin and paclitaxel responses in lung tumor cells
Cell Division (2023)
-
Increased expression of OPN contributes to idiopathic pulmonary fibrosis and indicates a poor prognosis
Journal of Translational Medicine (2023)
-
NGS-based profiling identifies miRNAs and pathways dysregulated in cisplatin-resistant esophageal cancer cells
Functional & Integrative Genomics (2023)
-
Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment
Cancer Immunology, Immunotherapy (2022)
-
Cisplatin loaded multiwalled carbon nanotubes reverse drug resistance in NSCLC by inhibiting EMT
Cancer Cell International (2021)
